Komori
Alfresa Holdings (2784) · FactFirst stated

FY2021-Q1: Lower Revenue and Profit in the Wholesale Business for Prescription Pharmaceuticals and Other Products

First written in FY2021-Q1. . Latest entry: FY2021-Q1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Revenue and Profit Decline in the Prescription Pharmaceutical Wholesale Business Due to Drug Price Revisions and COVID-19 ImpactA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021-Q1First statedAnnual report

    「当セグメントの当第１四半期連結累計期間の業績は、二度の薬価改定および新型コロナウイルス感染拡大等の影響により、売上高5,732億28百万円（前年同期比4.1％減）、営業利益29億94百万円（同62.6％減）となりました。」

    医療用医薬品等卸売事業は、二度の薬価改定と新型コロナウイルス感染拡大等の影響により減収減益となった。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.